Clinical Trials Browser

Active not recruiting × Brain Neoplasms × Nivolumab × Clear all

NCT04817254 2026-03-18

Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

Phase 2 Active not recruiting

Brain Neoplasms, Glioblastoma, Glioma, Gliosarcoma

NCT02910700 2025-12-17

Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma

Phase 2 Active not recruiting

CNSDermatologic

Brain Neoplasms, Melanoma

NCT02374242 2025-12-10

ABC

Phase 2 Active not recruiting

CNSDermatologic

Brain Neoplasms, Melanoma, Neoplasm Metastasis

NCT02696993 2025-11-10

Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer

Phase 1/2 Active not recruiting

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT04674683 2025-09-24

Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma

Phase 3 Active not recruiting

CNSDermatologic

Brain Neoplasms, Melanoma

NCT05341349 2025-07-30

Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases

Phase 1 Active not recruiting

CNSDermatologic

Uveal Melanoma, Brain Neoplasms, Melanoma

NCT05012254 2025-04-09

NIVIPI-Brain

Phase 2 Active not recruiting

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms